Sanofi has opened a new UK Headquarters, based at Thames Valley Park in Reading, Berkshire.
The company welcomed Matt Hancock, secretary of state for health and social care, to open the “state of the art” facility, along side Paul Hudson, chief executive officer of Sanofi and Hugo Fry, UK’s managing director.
The new 70,000 square ft. office facility marks a £37 million investment to Reading and will be the new base for 500 of the 1,200 employees in the UK.
“We are delighted to unveil our new headquarters and it has been an honour to welcome the Rt Hon Matt Hancock, secretary of state for health and social care, to today’s event,” says Hugo Fry, managing director at Sanofi in the UK.
He continued, “Thames Valley Park is well located and connected, but also home to global technology leaders and one of the best places for life sciences in the world. Just as delivering the best outcomes for the one million UK patients we support every month is important to us, we paid particular attention to designing a space that promotes the health and wellbeing of our employees.”
The company revealed that it is actively seeking to recruit at least 50 new roles in the coming months, in addition to ten graduate students via its new Aspiring Leaders programme.
By Anna Smith
Source: Pharma Times
Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.
Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.
On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.
